BPMC News and Press, Blueprint Medicines Corporation From 04/28/20

CAMBRIDGE, Mass. , April 28, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced top-line results from the Phase 3 VOYAGER clinical trial of avaprit...

Deals and Financings AkesoBio [HK:9926], a Zhongshan developer of novel mono- and bi-specific antibodies, staged a $335 million Hong Kong IPO and climbed 50% higher in its first trading session. The company's general strategy is to develop bispecific antibodies using a PD-1 antibody as a bac...

Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...

Shares of Deciphera Pharmaceuticals ( DCPH ) have risen by 20% since my August 2019 update called the stock a Buy based on ripretinib's impressive showing in fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST). Targeted oncology has been one of my favored themes to capita...

Systemic mastocytosis - overview Source: Blueprint Systemic mastocytosis [SM] is characterized by an excessive buildup of mast cells, typically, in the bone marrow or skin. Mast cells mediate inflammatory responses. There are five variants of SM which are grouped in two: Indolent sys...

Blueprint Medicines (NASDAQ: BPMC ) announces a pipeline update including topline data from the Phase 1/2 ARROW study evaluating pralsetinib (BLU-667) in patients with solid tumors. More news on: Blueprint Medicines Corporation, Healthcare stocks news, Read more ...

CAMBRIDGE, Mass. , April 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced the achievement of key milestones reflecting portfolio-wide pro...

As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...

Deals and Financings Abbisko Therapeutics, a Shanghai novel drug biopharma, raised $70 million in a Series C financing led by Singapore's Temasek. The company has four clinical programs underway, and it intends to expand its discovery pipeline, which consists of small molecule targeted oncol...

Blueprint Medicines ( BPMC ) announced that it had achieved positive results from a phase 2 study using its cancer drug avapritinib treating patients with indolent systemic mastocytosis (SM). Not only did this drug achieve the clinical endpoints, but it is able to move on to part 2 of th...